Asset Details
Do you wish to reserve the book?
Rationale and design of the prevail global trial program evaluating the prevail drug-coated balloon in patients with in-stent restenosis and de novo small vessel disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Rationale and design of the prevail global trial program evaluating the prevail drug-coated balloon in patients with in-stent restenosis and de novo small vessel disease
Do you wish to request the book?
Rationale and design of the prevail global trial program evaluating the prevail drug-coated balloon in patients with in-stent restenosis and de novo small vessel disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Rationale and design of the prevail global trial program evaluating the prevail drug-coated balloon in patients with in-stent restenosis and de novo small vessel disease
2025
Overview
•In-stent restenosis (ISR) and small vessel disease (SVD) remain difficult to treat.•Drug-coated balloons (DCB) are an alternative treatment option for ISR and SVD.•Prevail global is a clinical trial that will assess the prevail DCB in ISR and SVD.
In-stent restenosis (ISR) remains the leading cause of treatment failure following percutaneous coronary intervention (PCI) with contemporary drug-eluting stents. Especially in small caliber coronary arteries, restenosis is common following PCI and represents a treatment challenge. Drug-coated balloons (DCB) are an attractive alternative to stents for treatment of both ISR and small vessel disease. The safety and efficacy of the Prevail DCB will be assessed for (1) the treatment of ISR and (2) de novo lesions in small vessels.
Prevail Global is a prospective, international, dual cohort clinical study enrolling (1) patients undergoing PCI for ISR in a randomized controlled trial (1:1) design comparing the Prevail DCB versus an FDA-approved DCB (AgentTM, Boston Scientific Corporation, Natick MA), and (2) patients with de novo small vessel disease undergoing PCI with the Prevail DCB as part of a single-arm study compared with a historical control. The primary endpoint is target lesion failure, defined as a composite of cardiac death, target vessel myocardial infarction, or clinically-driven target lesion revascularization at 12 months post procedure. Patient follow-up is planned for 1 month, 6 months, and yearly through 5 years. Enrollment is expected to start in early 2025.
The Prevail Global study will directly assess the safety and efficacy of the Prevail DCB for the treatment of ISR and de novo small vessel lesions.
Prevail Global, NCT06535854, is registered at https://clinicaltrials.gov/study/NCT06535854.
Publisher
Elsevier Inc,Elsevier Limited
Subject
/ Angioplasty, Balloon, Coronary - instrumentation
/ Angioplasty, Balloon, Coronary - methods
/ Coated Materials, Biocompatible
/ Coronary Artery Disease - surgery
/ Coronary Restenosis - surgery
/ Coronary Restenosis - therapy
/ Coronary Vessels - diagnostic imaging
/ Coronary Vessels - pathology
/ Design
/ Drug-Eluting Stents - adverse effects
/ Female
/ Humans
/ Implants
/ Lesions
/ Male
/ Multicenter Studies as Topic
/ Patients
/ Percutaneous Coronary Intervention - adverse effects
/ Percutaneous Coronary Intervention - methods
/ Plasma
/ Randomized Controlled Trials as Topic
/ Stents
We currently cannot retrieve any items related to this title. Kindly check back at a later time.